Skip to content

RNTX RNTX Operating Income

Operating Income at other companies

Gilead Sciences logo
Gilead SciencesGILD
$2.59B+15.6%
AbbVie logo
AbbVieABBV
$3.99B+6.9%
CTO
Citius Oncology, Inc.CTOR
-$28.61M-283%
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
-$11.44M+27.5%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$9.36M-512%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$34.2M+59.2%

Other financials

Income statement

See full
Revenue-
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+177%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: RNTX’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's operating income?
RNTX (RNTX) reported operating income of -$5.23M in Q1 2026.
How has RNTX's operating income changed year-over-year?
RNTX's operating income increased by 6.8% year-over-year, from -$5.61M to -$5.23M.
What is the long-term trend for RNTX's operating income?
Over 4 years (2021 to 2025), RNTX's operating income has grown at a 17.5% compound annual growth rate (CAGR), from -$26.61M to -$50.63M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.